A Comparison of Oncologic Outcomes and Toxicity with Combined Modality Therapy vs. Carbon Ion Radiotherapy for Locally Recurrent Rectal Cancer in Previously Irradiated Patients
Elizabeth B. Jeans(Mayo Clinic), Michael G. Haddock(Mayo Clinic in Arizona), Hirotoshi Takiyama(National Institutes for Quantum Science and Technology), Joleen M. Hubbard(Rutgers, The State University of New Jersey), Hiroshi Tsuji(National Institutes for Quantum and Radiological Science and Technology), William S. Harmsen(Mayo Clinic), Kaitlin Qualls(Mayo Clinic), Christopher L. Hallemeier(Mayo Clinic in Arizona), David Cunningham(Royal Marsden NHS Foundation Trust), Anita Mahajan(Mayo Clinic in Arizona), Shigeru Yamada(National Institutes for Quantum Science and Technology), Kellie L. Mathis(Twitter (United States)), Robert L. Foote(Mayo Clinic), Krishan R. Jethwa(Mayo Clinic), Mark R. Waddle(Mayo Clinic), Kenneth W. Merrell(Mayo Clinic), Eric J. Dozois(Mayo Clinic)
International Journal of Radiation Oncology*Biology*Physics
October 25, 2021
Cited by 2
Related Papers
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
|JAMA|2010|1.4k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k